

# BIOVECTRA SIF Contribution Agreement – mRNA Vaccine and Biomanufacturing Center

## ➤ Strategic Innovation Fund (SIF) Funding awarded to BioVectra for the expansion of capabilities in the Biomanufacturing and Life Science Sector:

- **mRNA Capacity Expansion**, to create a specialty Biologics Manufacturing facility in **Charlottetown, PEI** by expanding current fermentation and synthetic capabilities. The project requires the reconfiguration of existing microbial fermentation and purification space to produce plasmid DNA from microbial sources and construction of a new structure for the manufacturing of mRNA.
- **Fill Finish Capacity Expansion**, to create a GMP formulation and fill finish area to support the new mRNA and pDNA expansions in **Charlottetown, PEI**.
- **Plasmid DNA (pDNA) Capacity Expansion**, to create a pDNA and mid scale single-use microbial manufacturing area within the **Windsor, Nova Scotia** facility. The space for single use fermentation and down stream purification will have the capacity to manufacture nucleic acids, protein subunits, and other microbial sourced therapeutics.
- **Process Development and Scale-up Expansion**, to establish new process development laboratories and scale-up area to support the process expansions in **Halifax, Nova Scotia and Charlottetown, PEI**.

*This capacity expansion is equivalent to 160 million doses of mRNA vaccine and a fill-finish capacity of 70 million doses annually*


### Contribution & Timeline

- Total project cost **CAD\$ 79.6 million**
- Total Federal government contribution of **CAD\$ 39.8 million**
- Total Provincial government contribution **CAD\$ 10.0 million**
- Project duration 2011/021 – 06/2023

### Benefits To Canada

- 125 new jobs in PEI and Nova Scotia
- Maintain 675 jobs in PEI and Nova Scotia
- 225 Co-Op terms in PEI and Nova Scotia
- R&D spend in Canada; Academic collaborations

# mRNA Vaccine and Biomanufacturing Center – Project Activities



Vaccine and Biomanufacturing Center  
PEI



Plasmid DNA Capacity Expansion  
Nova Scotia



Process Development and Scale up  
PEI and Nova Scotia

- Long-term capacity for pDNA & mRNA manufacturing for up to 160 million mRNA doses
- Fill Finish capability for 70 million doses
- Construction completed within 16 months

- Single use Facility for pDNA and other microbial based therapeutics
- First Canadian CDMO with 100 – 1,000L Single use microbial bioreactors
- Retrofit completed within 9 months

- State of the Art Process Development and Analytical Test Laboratories
- Cell line development to fill finish products
- Retrofit completed within 8 months

125 new FTE's - 225 CO-OP Terms - Collaborations with Canadian Academic Institutes - R&D Investments in Canada - Environmental Sustainability - Social Responsibility